Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma.
Liu YangXueqiong CaoNa LiBin ZhengMaobai LiuHongfu CaiPublished in: Therapeutic advances in medical oncology (2022)
From the perspective of US payers, in patients with unresectable MPM, NI has no economic advantage over C.